key: cord-0034747-o20z8ysd
authors: Majerciak, Vladimir; Zheng, Zhi-Ming
title: Detection of Viral RNA Splicing in Diagnostic Virology
date: 2012-04-05
journal: Advanced Techniques in Diagnostic Microbiology
DOI: 10.1007/978-1-4614-3970-7_38
sha: ae2dfee62504339ca1620ac65cd8e413354fa0f3
doc_id: 34747
cord_uid: o20z8ysd

Diagnostic virology is to identify the etiologic cause of infection from patient’s samples. In the past the diagnostic virology relied on three classical techniques to make a diagnosis of viral infection: (a) virus isolation by direct virus cultivation, (b) viral antigen detection, (c) indirect detection of virus-specific antibodies. While being important tools in the diagnostic virology today, these techniques are time-consuming and require specific tools such as cultivation media, cell or tissue cultures, antibodies, purified antigens. In the past decade the number of new molecular-based methods grew rapidly and gained more popularity in diagnostic labs. The core of these techniques constitutes of techniques based on nucleic acid detection by specific amplification, hybridization, and/or sequencing (reviewed in ref. [1]). The most nucleic acid-based diagnostic methods are simple, speed, sensitive and specific and thus meet the gold four-S-standard for their application in any diagnostic laboratories. The methods are simple and speed because only a specific primer pair and a PCR machine are needed in a lab setting and identification of a viral pathogen takes within few hours. They are sensitive and specific and require only a small amount of patients’ materials to detect a specific nucleotide sequence region. In general, these techniques can be used to detect almost all types of viral pathogens and even to identify multiple viral pathogens or their variants at the same time. In this chapter we focus on detection of viral RNA splicing as a new tool for diagnostic virology.

Diagnostic virology is to identify the etiologic cause of infection from patient's samples. In the past the diagnostic virology relied on three classical techniques to make a diagnosis of viral infection: (a) virus isolation by direct virus cultivation, (b) viral antigen detection, (c) indirect detection of virus-speci fi c antibodies. While being important tools in the diagnostic virology today, these techniques are timeconsuming and require speci fi c tools such as cultivation media, cell or tissue cultures, antibodies, puri fi ed antigens. In the past decade the number of new molecular-based methods grew rapidly and gained more popularity in diagnostic labs. The core of these techniques constitutes of techniques based on nucleic acid detection by speci fi c ampli fi cation, hybridization, and/or sequencing (reviewed in ref. [ 1 ] ). The most nucleic acid-based diagnostic methods are simple, speed, sensitive and speci fi c and thus meet the gold four-S-standard for their application in any diagnostic laboratories. The methods are simple and speed because only a speci fi c primer pair and a PCR machine are needed in a lab setting and identi fi cation of a viral pathogen takes within few hours. They are sensitive and speci fi c and require only a small amount of patients' materials to detect a speci fi c nucleotide sequence region. In general, these techniques can be used to detect almost all types of viral pathogens and even to identify multiple viral pathogens or their variants at the same time. In this chapter we focus on detection of viral RNA splicing as a new tool for diagnostic virology. ). An intron is de fi ned by several speci fi c sequence motifs which allow intron recognition by cellular splicing machinery. A 5 ¢ splice site or donor site GU at the intron 5 ¢ end is recognized by U1 small nuclear ribonucleoprotein (snRNP), a major component of the cellular splicing machinery. A 3 ¢ splice site or acceptor site at the intron 3 ¢ end consists of an AG dinucleotide, an upstream polypyrimidine track (PPT) and a further upstream branch point, which are recognized correspondently by U2AF35, U2AF65, and U2 snRNP. These initial recognitions of the intron elements by the components of RNA splicing machinery are essential for spliceosome formation on a pre-mRNA, leading to intron removal. ( b ) RNA splicing is catalyzed by two transesteri fi cation reactions. During RNA splicing the intron ( grey ) between RNA splicing is catalyzed by cellular splicing machinery consisting of several components: small nuclear ribonucleoproteins (snRNPs, U1, U2, U4, U5, and U6) and splicing factors. During initial step snRNP U1 and U2 recognized intron sequences at 5 ¢ splice site and branch point via complementary base-pairing, along with U2 accessory proteins U2AF65 and U2AF35 association with polypyrimidine track and 3 ¢ splice site, respectively ( Fig. 38.1a ) . Intron recognition is a signal for formation of a large protein complex called "spliceosome" where intron removal takes place [ 8, 9 ] by two transesteri fi cation reactions (Fig. 38.1b ) . First, the primary transcript is cleaved at the intron 5 ¢ end (5 ¢ splice site) to leave the upstream exon free and followed by branching of the cleaved intron 5 ¢ end to the branch point (usually A) to create a looped structure named "lariat intermediate." In the second step, the hydroxyl group of the free exon attacks the intron 3 ¢ splice site leading to the 3 ¢ splice site cleavage and lariat formation. Simultaneously, a covalent bound is created between two exons to create a mature mRNA. In general, the lariats are quickly released from the spliceosome and degraded in the nucleus.

The ef fi ciency of RNA splicing is regulated at multiple levels and both RNA cis -elements and cellular splicing factors play major roles in regulation of RNA splicing. As we described above, the level of conservation of the sequences at splice sites and branch point will affect the strength of binding of core splicing factors and determine the splicing ef fi ciency. RNA splicing is also modulated by a large family of cellular splicing factors containing serine-arginine-rich proteins (SR proteins) and heterogeneous nuclear ribonucleoproteins (hnRNPs). Most of the splicing factors differentially expressed in a speci fi ed tissues and/or a development stage are the RNA-binding proteins which bind to speci fi c RNA cis -element (splicing enhancers or silencers) located within introns and exons [ 10 ] . It is now well documented that splicing factors binding to the cis -elements either increase or decrease RNA splicing ef fi ciency depending on type of splicing factors, positions of the binding sites and overall spliceosome composition [ 11, 12 ] . Current studies showed that beside splicing factors, other processes such as RNA polymerase rate and chromatin structure also affect RNA splicing [ 13, 14 ] .

Although all introns in a pre-mRNA could be constitutively spliced out and all exons are supposedly included in a mature mRNA, there are many cases showing that an RNA splice site may be not selected constitutively, but rather skipped, during RNA splicing. Consequently, this alternative RNA splicing leads to production of RNA isoforms with different exon composition and sizes often resulting in production of different protein isoforms. In general, there are four major classes of alternative RNA splicing ( Fig. 38. 2 ), including exon skipping, intron retention, usage of alternative exons and usage of alternative 5 ¢ and alternative 3 ¢ splice site [ 15 ] . In addition, alternative promoter or polyadenylation usage can further complicate the alternative RNA splicing. The reason why some of the exons or introns in a pre-mRNA are alternatively spliced is because of the presence of weak or suboptimal splice signals in the RNA or lack of a particular splicing factor in that cell or tissue. It has been noticed that usage of weak splice sites is highly dependent on auxiliary splicing factors binding to the regulatory cis -elements. Since the expression of these factors is variable from cells to cells and from tissues to tissues, alternative RNA splicing is often associated with a speci fi c cell type, tissue, stage of cell differentiation [ 16 ] and results in various isoforms of transcripts from one gene [ 17 ] . Current analysis also revealed that number of genes with alternative RNA splicing increases with complexity of the organism and ranges from 0.05 % in yeast up to 66.8 % in human. Thus, alternative RNA splicing is the driving force behind the complexity of proteome in higher organisms other than total number of the mapped genes.

A mRNA generated by RNA splicing is different from its pre-mRNA. First, mRNA is smaller in size than its pre-mRNA due to RNA splicing which removes the introns found in the pre-mRNA. In contrast, the pre-mRNA not only is larger than the In addition, usage of alternative promoters (P1 or P2) or polyadenylation sites (pA1 or pA2) may affect exon composition in a fi nal mature transcript spliced mRNA but also has the same size as its DNA template. Second, mRNA contains exon-exon junctions with the sequence not present in DNA or its primary transcript allowing designing primers or probes to speci fi cally identify a particular mRNA isoform due to alternative RNA splicing. Although an alternatively spliced mRNA may translate a truncated protein which could be detectable with a speci fi c antibody, the molecular techniques based on detection of nucleic acids are more commonly used to detect RNA splicing.

Northern blot is one of the oldest techniques to detect RNA splicing. First, RNA molecules isolated from samples are separated based on size by electrophoresis in agarose or polyacrylamide gel. After transfer to a nitrocellulose or nylon membrane, the individual RNA transcripts are detected by an antisense probe speci fi c for the detecting RNA. The probes used for the Northern blot are usually labeled with 32 P isotope, enzyme (e.g. alkaline phosphatase), digoxigenin (DIG), or biotin and can be derived from a constitutive exon or an exon-exon junction ( Fig. 38 .3a ). Constitutive exon-based probes would detect all spliced RNA isoforms and the remaining, unspliced pre-mRNA and are recommended when the size difference between spliced RNA isoforms and unspliced pre-mRNA is suf fi cient enough to be separated. If the size difference is too small for two RNA isoforms to be distinguished, an exon junction probe could be used to speci fi cally detect a spliced product. In addition, a speci fi c probe from an alternative exon or intron could be also designed for detection of individual splicing isoforms derived from exon/intron inclusion.

RNase protection assay (RPA) requires most often 32 P-labeled single-stranded antisense RNA probes complementary to the transcripts of interest. The prepared probe(s) is consequently hybridized with sample RNA to form an RNA-RNA hybrid. Unhybridized single-stranded RNA is then removed by RNases A and T1 which digest single-stranded RNA only. The protected RNA fragments are separated in the gel by electrophoresis and their sizes are determined by molecular markers. To distinguish a spliced RNA product the probe should contain at least a partial intron region which will be digested from the probe due to lack of the intron sequence in the spliced mRNA. As a result, the protected probe by the corresponding exon regions of the detecting mRNA is shorter and will run faster in the gel ( Fig. 38.3b ). In general, RPA is more sensitive than northern Northern blot in detection of RNA splicing. Both Northern blot and RPA are commonly used in research laboratories. Their advantage is high speci fi city. However, both methods are very laborious and low-throughput requiring isolation of large amount (usually a few micrograms) of total RNA from samples and preparation of speci fi c probes often labeled with radioisotopes and thus making their limited usage in clinical diagnostics.

RT-PCR (reverse transcription-polymerase chain reaction) is one of the most commonly used methods for detection and quanti fi cation of RNA molecules. During RT-PCR RNA transcripts are converted into complementary DNA (cDNA) by reverse transcription using random hexamers or oligo-dT or transcript-speci fi c primers. The resulted cDNA is then used as a template in subsequent PCR with a pair of transcript-speci fi c primers. Detection of spliced RNA products by RPA. Diagram shows an antisense riboprobe spanning over an intron region (a solid thin line ) between two exons ( black boxes or solid thick lines ) and possible detection products. As an RNase used in the assay digests a single-stranded RNA region only, an RNA region base-paired with an antisense probe uniformly labeled with isotope 32 P will be protected from RNase digestion. In this diagram, the probe remains intact when binding to the pre-mRNA, while the probe binding to the spliced mRNA (lack of the intron) will cause the digestion of the probe intron region (single-stranded, dashed loop) resulting in production of smaller protected products corresponding to each exon

In principle the detection of spliced RNA transcripts by RT-PCR depends on amplicon selection and primer design. A most common approach is the ampli fi cation over the intron regions by a set of primers in fl anking exons. The resulted RT-PCR products vary in sizes depending on how the detecting transcript is spliced. A larger product than predicted size may represent an unspliced pre-mRNA or the contaminating genomic DNA. The later can be determined by a minus RT ampli fi cation (PCR). A spliced mRNA always gives a smaller RT-PCR product than its pre-mRNA due to removal of intron sequences by RNA splicing (Fig. 38.4a ). Another approach is to speci fi cally amplify a spliced product by using an exon junction primer because the sequence at exon-exon junction occurs neither in pre-mRNA nor in genomic DNA. Similarly, a primer based on an alternative exon would amplify only transcript with the inclusion of that exon (Fig. 38.4b ) . After ampli fi cation the size and amount of RT-PCR products are analyzed by gel electrophoresis. Because of nonlinear nature of PCR ampli fi cation the classical PCR only provides semi-quantitative data on the abundance of various spliced RNA isoforms.

Introduction of real-time quantitative RT-PCR (qRT-PCR) with a broad (10 7 ) dynamic range has signi fi cantly improved the sensitivity of RT-PCR. Because of high sensitivity real-time RT-PCR enables to detect and amplify RNA directly from a single cell without RNA extraction. In addition it automates the quanti fi cation and does not require electrophoretic separation of RT-PCR products.

Currently there are four major chemistries widely used in real-time RT-PCR: SYBR green (Molecular Probes), Taq Man™ probes [ 18 ] , Molecular Beacons [ 19 ] , and Scorpions™ probes [ 20 ] . The principles of different chemistries are described in Fig. 38 .5 . As of today, SYBR green and Taq Man™ probes represent the most common chemistries. SYBR green is a fl uorescent dye which has low fl uorescence when in solution; however, it becomes highly fl uorescent upon binding to double-stranded DNA. On the other hand, Taq Man™ probes, Molecular Beacons and Scorpions probes employ fl uorescence resonance energy transfer or Förster resonance energy transfer (FRET, also known as resonance energy transfer [RET] or electronic energy transfer [EET]) to generate fl uorescent signal. The FRET couples donor fl uorescent dye ( fl uorophore) with non fl uorescent quenching moiety (quencher). When fl uorescent dye is in close proximity of the quencher, the quencher molecule absorbs the energy and thus blocks fl uorescence emission from the fl uorophore when excited by light. TaqMan probes are 18-22 bp oligonucleotide probes which are labeled with a reporter fl uorophore at the 5 ¢ end and a quencher at the 3 ¢ end and thus in close proximity. Each probe is complementary to a region in the middle of the detecting target between two primers during PCR reaction. When Taq polymerase extends the primer to synthesize the nascent strand, the 5 ¢ -3 ¢ exonuclease activity of the Taq polymerase degrades the Taq Man™ probe annealed to the targeted region and releases the fl uorophore from Taq Man™ probe and thereby breaks the close proximity to the quencher. As a result, the fl uorophore when excited by cycler's light emits fl uorescence which marks the presence of PCR product. The method determines the amount of product by generation of fl uorescent signal, which is measured in "real time" during entire length of RT-PCR reaction enabling to calculation of the amount of PCR product after each ampli fi cation cycle. Similarly to Taq Man™ the Molecular Beacon and Scorpions™ use probes to detect speci fi c PCR product. However, instead of probe degradation the signal is generated by physical separation of fl uorophore and quenching moieties after hybridization of speci fi c probe to PCR product during ampli fi cation (Fig. 38.5 ) .

Each chemistry has its own advantages and disadvantages which need to be considered during experimental design. SYBR green represents a simple, easy-to-use, and the most economical real-time RT-PCR method. Disadvantage of SYBR green N  R  e  v  i  t  a  n  r  e  t  l  A  .  I  I  g  n  i  c  i  l  p  s  A  N  R  e  v  i  t  u  t  i  t  s  n  o  C  .  I 

Detection of spliced RNA products by RT-PCR. Intron removal from a pre-mRNA could be detected by RT-PCR based on the size of a product (a) or in a selective ampli fi cation (a and b) . ( a) A pair of primers (Pr1 and Pr2) used for ampli fi cation are derived from two constitutive exons ( black boxes ) over an intron ( solid line ) and the ampli fi ed mRNA product (spliced) will be smaller in size than the products ampli fi ed from template DNA or unspliced pre-mRNA. In an alternative RNA splicing assay, a pair of primes is derived from exon 1 and exon 3 spanning over alternative exon 2 ( grey box ). Alternative RNA splicing will result in multiple spliced RNA products of various sizes ampli fi ed by RT-PCR. (b) Speci fi c ampli fi cation of spliced RNA products during constitutive or alternative RNA splicing. The speci fi c splicing products could be obtained by using a set of primers in which one represents a splicing junction ( Pr1 ). Because of lack of this sequence in unspliced pre-mRNA or DNA, only the spliced product will be selectively ampli fi ed. A selective ampli fi cation could be also used to amplify by RT-PCR a speci fi c RNA isoform derived by alternative RNA splicing by using one primer in an alternative exon (exon 2) in combination with a primer in exon 3. In this case, only the spliced product with exon 2 inclusion will be selectively ampli fi ed by RT-PCR is its binding nonspeci fi cally to any DNA including primer dimers and nonspeci fi c PCR products and is not useful for multiplex ampli fi cation of several products in the same reaction. In contrast, Taq Man™, Molecular Beacons, and Scorpions™ probes speci fi cally detect only a PCR product complementary to probe sequence enabling to distinguish speci fi c from nonspeci fi c products. Disadvantage of these chemistries is that each PCR product requires synthesis of its own speci fi c probe which increases the cost per reaction. On the other hand, labeling individual probes with fl uorophores of different emission spectrum allows multiplexing and simultaneous detection of several products and reduces the cost and labor. The usage of real-time RT-PCR for splicing detection requires special considerations. Since real-time RT-PRC techniques omit electrophoretic separation, the spliced product could not be distinguished based on size. Therefore it is important that only desired product is ampli fi ed. In this case, the usage of SYBR green chemistry is the most challenging because of the lack of speci fi city. Probe-based methods provide higher speci fi city due to probe hybridization to selected sequences which are not present in nonspeci fi c products. To detect only desired spliced product the probe and primer should be complementary to a speci fi c exon-exon junction or alternatively spliced region. Several other factors must be considered when using RT-PCRbased techniques in diagnostics including RNA sample quality and preparation, Taq polymerase inactivating contaminants in clinical samples, and ampli fi cation bias. Other considerations are false positivity and PCR cross-contamination.

DNA microarrays (also known as DNA chips) are composed of large number of probes, often in several thousands, spotted on very small area in 2D format on solid surface (glass or plastic). Probes represent DNA oligos of various length and chemistry. Each probe has speci fi c DNA sequence allowing detection of corresponding DNA with complementary sequence. Currently, there are two major technologies of DNA arrays manufacturing of microarray: (a) direct synthesis of probes on the array or (b) printing arrays from library of presynthesized probes. Each DNA microarray allows rapid pro fi ling of large number of DNA molecules at the same time. Today DNA microarrays are widely used to study gene expression pro fi ling and RNA posttranscriptional modi fi cations including RNA splicing [ 21 ] .

The analysis of RNA transcripts by DNA microarrays requires a conversion of RNA samples to DNA by reverse transcription, following ampli fi cation and labeling with fl uorescent dye. After labeling the samples are hybridized with the probes on the array. Unbound samples are washed away and the fl uorescent signal is captured and analyzed by microarray readers (Fig. 38.6a ). The intensity of fl uorescent signal corresponding to the number of bound molecules allows determination of the level of RNA in the original sample by mathematical algorithm.

There are two different approaches in probe design to study of RNA splicing using DNA microarrays: tiling and exon arrays [ 22 ] (Fig. 38.6b ). In tiling arrays the set of overlapping probes cover the full-length of nascent primary transcript including exons and introns. The analysis of fl orescence for each probe allows to identify exons and introns based on the difference in signal intensity ( Fig. 38 .6b i ). The advantage of tiling arrays is their ability to identify known as well as new splice events. Therefore, the tilling arrays are often used as discovery tools. The disadvantages are . When bound to unspliced transcript the binding sites of two probes are separated by intron preventing energy transfer by FRET and thus, no signal is generated. After intron removal by RNA splicing, two probes are bought to close proximity for FRET to occur. The energy transfer from the donor to the acceptor leads to excitation of the acceptor fl uorophore (A in circle with spikes ) and generation of detectable signal. The diagram is modi fi ed from Blanco and Artero [ 31 ] requirement of large amount of probes and are time-consuming data analysis. The exon arrays are more commonly used but require the knowledge of splicing events. Several types of probes hybridizing to fl anking exons, intron, and exon-exon junctions are designed to detect each splicing event ( Fig. 38.6b ii ). The fl uorescence intensity is detected for each probe and mathematical model is applied to determine the occurrence of splicing event. The advantages of exon arrays are: the requirement of smaller number of probes with simpler data analysis. However, the exon arrays detect only known or predicted splicing variants. Due to their large capacities the exon arrays could be designed to detect splicing in multiple viral pathogens.

Tissue sections historically represent an important tool in diagnostic of pathological changes during viral infection and detection of viral pathogens on cellular level. There are two major types of tissue sections: frozen and formalin-fi xed, paraf fi n-embedded (FFPE). Both are routinely used for detection of viral antigens by various types of staining, but their use in detection of nucleic acids including spliced transcripts is still rather rare. Improved sensitivity of current nucleic acid isolation and ampli fi cation techniques allows the recovery of nucleic acid from tissue sections for further analysis by PCR and RT-PCR with selective isolation of only cells of interest by laser capture microdissection to bring additional level of speci fi city [ 23, 24 ] . However, detection of nucleic acids by in situ hybridization (ISH) directly on tissue sections can provide additional bene fi ts about gene expression linked with spatial distribution of speci fi c RNA transcripts at cellular and often even at subcellular level. In the past the nucleic acid molecules including RNA transcripts by ISH were detected by DNA probes labeled with radioisotope ( 35 S, 33 P, 3 H) [ 25 ] , which were later replaced by nonradioactive DNA-probes labeled with biotin or digoxigenin and detected by chromogenic methods using enzymes-labeled antibodies (CISH) [ 26 ] . Labeling probes speci fi c for different transcripts with different fl uorophores (FISH) allow detection of multiple targets at the same tissue section. However, the sensitivity was always a limiting factor of ISH techniques. This was caused mainly by usage of DNA probes which suffer from low af fi nity to complementary RNA targets and sensitivity to degradation of RNA-DNA hybrids by RNase H. Development of tyramide signal ampli fi cation (TSA) has dramatically improved the sensitivity of DNA probes [ 27 ] . Further improvement came from by introduction of locked nucleic acids (LNA) and peptide nucleic acids (PNA) probes with high af fi nity to RNA molecules and resistance to RNase H degradation [28] [29] [30] . Detection of RNA splicing by ISH requires a probe to speci fi cally bind only to spliced mRNA without binding to unspliced pre-mRNA or genomic DNA in the sample. Historically this was achieved by designing a probe over exonexon junction containing sequences present only in spliced transcripts ( Fig. 38 .6c i ).

Another approach in detection of spliced transcripts by IHS represents the methods by cohybridization of two probes labeled with donor and acceptor fl uorophore and generation of signals by FRET. In principle, each splicing event is monitored by a set of two probes complementary to exonic sequences fl anking an intron region. One of two probes carries a fl uorophore acceptor while the second probe is labeled by fl uorophore donor. When probes bind to genomic DNA or unspliced nascent transcript their binding sites are separated by intron regions resulting in distance between donor and acceptor too big for two fl uorophores to engage in FRET. However, intron removal by splicing brings probe binding sites to proximity close enough for FRET to occur resulting in generation of measurable fl uorescence [ 31 ] (Fig. 38.6c ii ). This results in high speci fi city and low background. Using a set of probes with different fl uorophores allows to detect multiple spliced transcripts or various spliced isoforms of the transcript. In summary, ISH hybridization methods provide us with a necessary tool to investigate the distribution not only of protein-encoding transcripts but also of rapidly growing number of virus-encoded noncoding RNAs, of which their role in viral pathogenesis remains often elusive [ 32 ] . In situ hybridization methods could be especially suitable in retrospective analysis of archived samples in collections.

Next-generation sequencing (NGS) represents a new generation of analytical tools for genome and transcriptome analysis [ 33 ] . It bases on generation of a large amount of short sequences in parallel sequenced reactions. Advantages of NGS are the requirement of less amount of the initial sample, deep coverage, and nucleotide resolution. NGS also does not require any previous knowledge of detecting sequence. Currently there are several platforms including 454 Life Sciences ( Roche ), Genome Analyzer ( Illumina ), ABI Solid Sequencing ( ABI ), and many others. Each platform uses different technology to generate the data, but all provide the same information.

Sequencing of RNA samples converted to cDNA is called RNA-seq . RNA-seq provides a comprehensive picture of whole genome transcriptome and has been successfully used for analysis on gene expression and posttranscriptional processing including RNA splicing. However, NGS is costing and requires sophisticated data analysis, which makes it less suitable for clinical diagnostics. However, RNA-seq does not require any prior knowledge of detecting sequence composition and therefore allows to detect unknown or unpredicted RNA sequences. This may be especially bene fi cial in discovery of new pathogens including viruses [ 34 ] . In addition, RNA-seq instantly analyzes a transcriptome including spliced transcripts of any type of cells or tissues.

RNA splicing does not occur in prokaryotes and is a hallmark of the eukaryotic gene expression. In eukaryotes the number of genes which undergo splicing varies highly from organism to organism, with only about 5 % of all genes being spliced in yeasts to 95 % in human [ 35, 36 ] . Viruses as intracellular parasites replicate inside of host cells and hitchhike many cellular processes for their multiplication including RNA splicing. By using constitutive and/or alternative RNA splicing, most of DNA viruses and some of RNA viruses increase complexity of their proteome without requirement of additional genetic materials.

Detection of spliced viral mRNAs in clinical samples would provide several bene fi ts. While detection of viral genomes in clinical samples would indicate virus infection, the result does not provide information about the stage and dynamic of virus infection. In many cases the progress of viral replication could be assumed from changes in viral load, but this approach requires multiple sampling in the course of infection and varies between individuals. One major advantage for detection of spliced viral transcripts is that viral RNA splicing re fl ects viral gene expression and thus active viral infection, providing important information about the status of infection without requiring multiple sampling. The production of viral transcripts and their RNA splicing are often the fi rst sign of virus replication detectable before the increase of viral load or occurrence of viral-speci fi c antigens or antibodies. Therefore the detection of active viral infection by RNA splicing may be especially important for the early viral diagnosis of the infection critical for successful treatment. Because of direct association of spliced viral transcripts with the level of active viral replication and by monitoring viral RNA one could provide essential information earlier enough for initiation of antiviral therapy. A rapid shut-off of viral transcription and RNA splicing could be also the fi rst sign of the blockage of viral replication visible even before the change in viral load by genome copy numbers. In the case of ubiquitous viruses, such as members of herpesvirus or parvovirus family, which establish latent infection in the host, detection of RNA splicing of a viral early gene would assist to distinguish viral latent infection from active infection. Such a diagnosis is critical for recipients of the transplant organs where reactivation of latent viruses often leads to transplant rejection.

In addition, interpretation of RNA splicing detection results is straight forward without worrying carryover DNA contamination as a spliced RNA is smaller than its corresponding DNA template. As we describe above, there are many techniques available today for RNA splicing assay. These techniques are not only easy to set up with a low cost comparing to virus isolations and immunological methods, but could be quickly applied to detect new emerging viruses which cultivation of the virus is impossible and/or no immunological method is available. This is particularly true in combination of RNA-seq which can rapidly provide sequence information about a viral transcriptome and RNA splicing of viral messages.

In fl uenza virus infection affects millions of people every year. In fl uenza viruses, including in fl uenza virus A, B, and C, are the members of Orthomyxoviridae family. In fl uenza viruses are enveloped RNA viruses with a segmented, single-stranded RNA genome of negative polarity (ssRNA−). Number of segments may vary between virus species, with in fl uenza viruses A and B genome having eight segments and in fl uenza C seven segments. In contrast to the majority of RNA viruses the in fl uenza viruses replicate in the nucleus of host cells because of their dependence on cellular expression machinery [ 37 ] . During replication viral RNAs are produced by viral RNA-depended RNA polymerase. However, viral RNA genomes use short sequences with a cap structure generated by host RNA polymerase II for priming to initiate viral transcription. During infection viral polymerase produces two types of RNAs: one for protein synthesis and the other served as a template for viral genome replication (see review ref. [ 38 ] ).

RNA splicing in in fl uenza viruses was fi rst detected in an RNA transcript from the smallest segment 8 in in fl uenza A and B and their corresponding segment 7 in in fl uenza C. This transcript encodes two nonstructural viral proteins: larger NS1 and smaller NS2 [ 39 ] . In in fl uenza A, NS1 protein is encoded by an unspliced primary RNA transcript (~890 nts), whereas NS2 protein is expressed from a spliced RNA (~350 nts) generated by removal of a 473-nt intron from its primary RNA transcript. This leads in fl uenza A NS1 and NS2 proteins sharing the same AUG start codon and fi rst nine amino acid residues. Translation of NS2 protein continues in +1 frame after RNA splicing and this leads the C-terminal NS2 partially overlapping the NS1 by 70 amino acid residues [ 40 ] ( Fig. 38 .7a ). Similar splicing event for production of NS1 and NS2 proteins has been detected from infections of in fl uenza B [ 41 ] and in fl uenza C [ 42 ] viruses.

In fl uenza A segment 7 which encodes M1 and M2 proteins produces three RNA species by alternative RNA splicing. The unspliced RNA which is collinear with the genome encodes M1 nucleoprotein with 252 amino acid residues and the two alternatively spliced RNAs M2 and mRNA3 [ 43 ] share the same 3 ¢ splice site at nt 740 position, but use different 5 ¢ splice sites for alternative RNA splicing ( Fig. 38 .7b ). M2 RNA uses a 5 ¢ splice site at nt 51 position, whereas mRNA3 employs another 5 ¢ splice site at nt 11 position from the beginning of viral speci fi c sequences. M2 protein bears ion channel activity and shares nine amino acid residues with the M1 N-terminus. The mRNA3 contains a short open reading frame in its exon 2 with potential to encode a short peptide of nine amino acid residues. However, the expression of this peptide was never experimentally con fi rmed. The role of this transcript during virus replication remains unknown.

While M2 and mRNA3 transcripts are detectable in cells infected with all in fl uenza A viruses, some strains, like A/WSN/33, produce additional spliced transcript named mRNA4 [ 44 ] . mRNA4 is generated by usage of additional 5 ¢ splice site at position nt 146 and share the same 3 ¢ splice site with M2 and mRNA3 at position nt 740 (Fig. 38.7b ). mRNA4 has potential to encode a peptide with 54 amino acid residues and its fi rst 37 amino acid residues are identical with M1 protein. Sequence analysis of more than 6,000 in fl uenza strains revealed that about 20 in fl uenza A strains has conserved mRNA4 splice site [ 45 ] . Sequence information of all in fl uenza viruses could be found at http://www. fl u.lanl.gov/ .

The primary RNA transcript of segment 7 in in fl uenza virus B does not undergo alternative splicing to produce M2 protein as in case of in fl uenza A. RNA splicing in M transcript takes place with segment 6 of in fl uenza C [ 46 ] . Two transcripts generated from segment 6 in the infected cells are the full-length primary and single spliced transcript by removal of an intron located at the 3 ¢ end of the primary transcript. The primary transcript contains a 374-aa ORF (P42), but the spliced message contains a shorter ORF encoding 242-aa residues (CM1) due to generation of STOP codon after RNA splicing from nt 751 5 ¢ splice site to nt 982 3 ¢ splice site Horvath [ 38 ] . ( c ) Oligo primers used for RT-PCR to detect spliced RNA products from segment 7 of in fl uenza A/WSN/33 (H1N1) as described [ 207 ] . cRNA, complementary RNA; vRNA, virion RNA ( Fig. 38.7b ). P42 protein is consequently processed by internal cleavage, resulting in production of a predominant CM2 protein containing the C-terminal 115-aa residues of P42 protein [ 47, 48 ] . In summary, there are two instances of viral RNA splicing in in fl uenza infection: one conserved between all three species (NS1) and the second highly variable in each species (M). Thus, combination of NS1 and M RNA splicing assays would reveal not only active in fl uenza virus infection, but also specify the infection with a speci fi c in fl uenza virus species.

Human immunode fi ciency virus (HIV) causing acquired immunode fi ciency syndrome (AIDS) is a member of Lentivirus genus in retrovirus family. HIV infects cells of immune system consequently causing the failure of immunity associated with occurrence of opportunistic infections leading to death. HIV infection is considered pandemic with about 0.6 % of world population being infected. Two types of HIV viruses were characterized. Although closely related, HIV-1 differs from HIV-2 in infectivity and geographical distribution, with HIV-2 much less pathogenic in several West African countries.

HIV is an enveloped virus and carries a single-stranded RNA genome in size of 9-kb of positive polarity (ssRNA+). After initial infection the viral genomic RNA is converted by virus-encoded reverse transcriptase into DNA which then could integrate into host genome where the integrated viral genome resides as a provirus. Later, the integrated provirus serves as a template for transcription of viral transcripts.

In contrast to simple retroviruses, HIV genome has high coding capacity. Besides encoding viral structural and replication proteins ( gag , pol , env ) HIV expresses a large numbers of accessory proteins. This is achieved by production of over 40 RNA isoforms derived from single RNA transcript by extensive alternative RNA splicing [ 49 ] (Fig. 38.8a ) .

Three groups of HIV transcripts could be observed by size in Northern blot analysis. The fi rst group represents an unspliced 9-kb transcript which serves a template for The second group represents single spliced RNA transcripts in size of ~4-kb which encode env , vif , vpr , and vpu proteins. The third group in size of ~2-kb consists of multiple spliced RNA transcripts to encode accessory proteins tat , rev , nef , and vpr . During virus infection, HIV generates such a wide variety of RNA transcripts by usage of at least fi ve alternative 5 ¢ splice sites and 8-9 alternative 3 ¢ splice sites [ 50, 51 ] ( Fig. 38.8b ). In addition, several antisense transcripts initiating from several 3 ¢ long terminal repeats (3 ¢ LTR) were also detected in HIV-1-infected cells [ 52 ] . Recent studies showed that HIV RNA splicing is largely regulated by viral RNA cis -elements and cellular splicing factors and is orchestrated for completion of HIV life cycle in the course of virus infection. Multiple spliced transcripts of 2-kb family are expressed in the early stage of virus infection to express tat , rev and nef. This group of spliced RNAs is produced by using 3 ¢ splice site A3-A5 located in the central part of the viral genome with A3 site for expression of tat , A4a-c for rev , and A5 for nef proteins. During late stage of HIV infection, nuclear import and accumulation of tat together with rev protein allows the rev protein bind to a rev-responsive element (RRE) in partially spliced 4-kb and unspliced 9-kb RNA transcripts located in tat/rev intron between D4 and A7 splice sites to mediate the later transcripts export into the cytoplasm for translation [ 53 ] (Fig. 38.8c ) . Sites A1A and D1A are involved in pre-mRNA stability [ 54 ] . Strains from IIIB family of HIV viruses use additional A6 and D5 to generate small exon in env region and the transcripts containing this exon express tripartite tat-env-rev fusion protein, tev [ 55, 56 ] .

Regulation of HIV RNA splicing depends on the selection of 3 ¢ splice sites which are, in general, weak in contrast to strong and highly active 5 ¢ splice sites. In addition, numerous positive and negative splicing regulatory cis -elements identi fi ed in HIV RNA genome bind various cellular splicing factors and affect the selection of individual 3 ¢ splice site (see review ref. [ 49 ] ). Comparison of nucleotide sequences between various clades of HIV-1 has shown a high level of conservation of splice sites among different clades of HIV-1 strains (except D4a, b, c).

Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) were fi rst two retroviruses discovered in human [ 57 ] . HTLV-1 is etiologically linked to adult T-cell leukemia/lymphoma (ATLL), an aggressive malignancy of CD4+ T lymphocytes, as well as to a neurological disorder named HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) [58] [59] [60] . HTLV-1 is endemic in Japan, Africa, Caribbean basin and South America. HTLV-2 is linked to HAM/TSP but not to ATLL. HTLV-2 infection occurs predominantly in parts of Africa and Americas [ 61 ] .

HTLV-1 and -2 are two closely related complex retroviruses sharing about 70 % of nucleotide sequences. Their genome organization and replication is similar to HIV. Besides essential genes ( gag/pol/env ) expressed from the full-length or single spliced RNA, HTLVs also encode a number of accessory proteins from a pX region [ 209 ] . Nucleotide positions are based on a full-length HTLV-1 cDNA (GenBank Accs. No. L03562.2) located in the 3 ¢ end of virus genome (Fig. 38.9a ) . Transcripts for encoding accessory proteins are generated by alternative RNA splicing of a full-length primary transcript using several 5 ¢ splice sites and 3 ¢ splice sites (Fig. 38 .9b ) (reviewed in ref. [ 62 ] ). Recently transcripts antisense to pX region have been discovered in the infected cells either with HTLV-1 or HTLV-2 and these antisense transcripts encode HBZ and APH-2 proteins, respectively [ 63, 64 ] . Interestingly, these transcripts also undergo RNA splicing.

In contrast to HIV-1 the regulation of HTLVs RNA splicing and the roles of cellular splicing factors in HTVL RNA splicing are poorly understood.

Human circovirus TT virus (TTV) was originally discovered in the serum of a patient with posttransfusion non-A-G hepatitis [ 65 ] . Later studies showed that TTV is present in body fl uids of healthy individuals and is not associated with any pathological disorder. However, the prevalence of TTV in general population appears highly variable from about 2 to 90 % of the incidence of TTV infection. These large variables among the reported studies are most likely attributable to primer selection and PCR performance [ 66 ] . TTV isolates have considerable diversity (about 30 %) which could be clustered in several genotypes groups without any particular geographical distribution, indicating that TTV represents a rather ubiquitous virus. Virus replication, route of TTV infection, and association with pathological manifestations remain unclear.

TTV is small nonenveloped virus of icosahedral architecture and contains a circular single-stranded DNA genome in size of 3.6-3.9 kb of negative polarity (ssDNA−) [ 67, 68 ] . TTV replication is not yet fully understood partially due to the lack of supportive tissue culture system. TTV genome consists of a GC-rich noncoding region and a protein coding region with two overlapping ORFs (Fig. 38.10a ) . Three species of RNAs in sizes of 2.8-, 1.2-, and 1.0-kb were detected in infected bone marrow cells as well as in an in vitro infected cell line [ 69, 70 ] . All transcripts originate from the same promoter and undergo alternative RNA splicing (Fig. 38.10b ) . Each RNA transcript could be translated into two different proteins by using two alternative start codons [ 71 ] . The presence of other ORFs (ORF3 and 4) in TTV genome was predicted, but has not con fi rmed yet.

The role of TTV RNA splicing and its regulation in virus infection and virus production remained largely unknown. Another human circovirus TTV-like mini virus (TLMV) has recently been identi fi ed in human sera [ 72 ] . TLMV shares same genetic organization with TTV and other circoviruses, but its genome is only about 2.9-kb in size.

Hepatitis B virus (HBV) chronic infection leads to development of liver cirrhosis and hepatocellular carcinoma [ 73 ] . Despite an effective HBV vaccine is available in many countries, HBV infection remains epidemic in many parts of the world, particularly in Asia and sub-Saharan Africa. WHO estimates that HBV infects about two HBV is a noncytopathic, hepatotropic virus. Its genome consists of a 3.2-kb long circular and partially double-stranded DNA. HBV encodes four viral proteins: core (C), reverse transcriptase-polymerase (P), surface (S) and X-protein (Fig. 38.11a ) . In infected hepatocytes viral DNA is converted to cccDNA (covalently closed circular DNA) and serves as a template for expression of viral pregenomic (pgRNA) and three subgenomic RNAs from several promoters. Despite the presence of several promoters, all transcripts used the same poly A signal for transcription termination (Fig. 38.11b ) . The core protein C and polymerase-transcriptase protein P are encoded by a bicistronic pgRNA. Subgenomic preS and S RNAs translate three surface antigens (large [preS1], middle [preS2], and small [S] surface antigens). A short RNA in size of 0.7 kb encodes X protein, a nonstructural viral protein presumably with oncogenic potentials [ 74 ] . A precore RNA initiated upstream of the pgRNA encodes HBeAg [ 75, 76 ] . Beside protein translation pgRNA is a template for reverse transcription into a genomic minus DNA strand during HBV genome replication.

All HBV transcripts from cccDNA are produced by cellular RNA polymerase II. A spliced 2.2-kb RNA transcript was fi rst identi fi ed in transfected hepatoma cells [ 77 ] and contains a single 1,223-nt long intron starting from the end of core antigen ORF to the middle of S antigen ORF. Subsequently, other single and multiple spliced forms of pgRNA were discovered in sizes of 2.1-2.6-kb from cell cultures and liver tissues of HBV patients [78] [79] [80] . So far, 13 spliced variants of pgRNA and two spliced isoforms of pre-S2/S RNA have been identi fi ed during HBV gene expression infection and these spliced viral RNAs are produced by using six 5 ¢ splice sites and seven 3 ¢ splice sites (Fig. 38.11c ) . A viral cis -element PRE (posttranscriptional regulatory element) and cellular splicing factors such as PTB (polypyrimidine track-binding protein) and SR-proteins may play roles in regulation of HBV RNA splicing (see review ref. [ 81 ] ).

Approximate 30-50 % of HBV RNA are spliced RNAs during HBV infection of human hepatoma cell lines Huh7 and HepG2, two popular cell lines for in vitro HBV replication studies [ 82 ] . Huh7 cells seem to produce more spliced RNA than Hep2G cells. The major spliced product is derived from 30 % of pgRNA using nt 2,447 5 ¢ ss and nt 489 3 ¢ ss in genotypes A, C, D, E. Serum of infected patients or hepatocarcinoma tumor samples frequently contain HBV DNA originated from spliced variants [ 83, 84 ] . Level of spliced HBV RNAs in patients varies widely from no splicing to extensive splicing and is related to viral genotype [ 85 ] . Role of HBV RNA splicing in HBV life cycle or pathogenesis remains to be elucidated. HBV spliced RNAs express two new proteins [ 86, 87 ] . A spliced mRNA derived from pgRNA with removal of a 454-nt intron from nt 2,447 to 2,901 encodes a structural polymerase-surface fusion protein (P-S FP) p43 with potential function in the entry [ 86 ] . Another single spliced pgRNA with removal of an intron from nt 2,447 to 489 translates a 93-aa fusion protein in size of 10.4-kDa, of which its fi rst 46-aa residues are identical to the N-terminus of viral polymerase protein followed by the 47-aa residues generated by the frameshift from the second exon. This protein has been It has been assumed that alternative RNA splicing of HBV preC and preS1leads to production of defective HBV viral particles. Diagrams are modi fi ed from Sommer and Heise [ 81 ] . Arrows below the transcripts are two sets of primer pairs used to detect spliced pgRNA products of HBV by RT-PCR [ 210 ] as detailed in (d) with primer positions and sequences derived from HBV TK113 genome (GenBank Accs. No. JF754635) referred as hepatitis B splice-generated protein or HBSP [ 87 ] and could be associated with HBV chronic infection, viral cytopathogenic effect, and immune evasion (see review ref. [ 88 ] ).

Parvoviruses are a group of small nonenveloped viruses containing a single-stranded DNA genome (ssDNA) in size of ~6-kb. The palindromic inverted terminal repeats at the ends of virus genome function as an origin of replication. Parvoviruses replicate via a double-stranded DNA intermediate which serves as a template for viral transcription [ 89 ] . Replication of some parvoviruses relies on "helper" virus such as adenovirus, herpesviruses, vaccinia virus, and human papillomaviruses [90] [91] [92] .

Parvoviruses are ubiquitous viruses and infect a wide range of animals. As of today, there are at least four members of Parvoviridae family that are infectious to humans: adeno-associated viruses (AAV), parvovirus B19 (B19V), human bocaviruses (HuBoV), and human Parv4 [ 93 ] . Despite of structural and genetic similarity, different parvoviruses use different replication and transcription strategies during virus infection and have different host tropism to initiate a productive infection in the presence of a helper virus.

Adeno-associated viruses (AAV), currently classi fi ed as Dependoviruses , were fi rst human parvoviruses identi fi ed in the group. AAVs infect wide range of species with AAVs-1, -2, -3, -8, and -9 being found in human [ 94 ] . Currently no disease or pathological condition is associated with AAV infection in human. The correlation between AAV infection and fetal loss and male infertility was proposed due to high prevalence of AAV DNA in placental tissues and in genital tissues of men with abnormal semen [ 95, 96 ] . Because AAV lacks pathogenicity, induces low immune response, infects both dividing and nondividing cells with capability of viral DNA integration into the host genome, AAV has gained attention as a vector for gene therapy (see review ref. [ 97 ] ).

All AAV genomes consist of two open reading frames, Rep and Cap , with Rep for virus replication and Cap for structural capsid protein. AAVs use several different strategies to produce viral products. First group represents AAV1, AAV2, AAV3, AAV4, and AAV6 and their viral transcripts originate from one of three viral promoters on the left hand side of viral genome and are terminated on a single polyadenylation site on the right hand side of the genome. The middle part of the transcripts contains a ~300-nt long intron with a nonconsensus 5 ¢ splice site and two 3 ¢ splice sites (Fig. 38.12a ) .The ef fi cient splicing requires the presence of both helper virus and large Rep protein [ 98 ] . While Rep protein seems to be essential for AAV2 splicing, several adenovirus proteins (E1A, E1B, E2a, E4 or f6, and VA RNA) as well as some products of herpes simplex virus (UL5, UL8, UL52, and UL29) have stimulatory effect on AAV2 splicing [ 99 ] . AAV5 and some animal AAVs are in the second group which utilizes three upstream promoters for their transcription, but their genome contains additional polyadenylation sites in the intron region. Transcripts from two upstream promoters are polyadenylated on the internal polyA site, whereas spliced transcripts from P41 promoter use a poly A site at the right side of the genome (Fig. 38.12b ) . The only spliced transcript in AAV5 infections is the Cap transcript which contains a smaller (~240-nt) intron. Interestingly, the splicing of AAV5 Cap transcript is constitutive and highly ef fi cient even in the absence of helper virus infection [ 100 ] . Human B19 virus, member of Erythrovirus genus, was fi rst identi fi ed in the serum of blood donor [ 101 ] . Three of B19 viruses have been identi fi ed from different geographic regions [ 102 ] . After acute infection the virus persists in host for the rest of the life. The infection by B19 virus is in general asymptomatic, but several pathological conditions are associated with B19 infection and these include erythema infectiosum (the " fi fth disease") [ 103 ] , polyarthropathy syndrome [ 104 ] , transient aplastic crisis (TAC) [ 105 ] , and persistent anemia/pure red cell aplasia (PRCA). B19 infection during pregnancy may associate with spontaneous miscarriage and development of nonimmune hydrops fetalis [ 106 ] .

Similar to other parvoviruses, B19 virus genome encodes two large open reading frames. NS1 ORF on the left-side genome translates a 77-kDa nonstructural protein and a VP ORF on the right-side genome produces two capsid proteins (84-kDa VP1 and 58-kDa VP2). At least nine virus-speci fi c transcripts have been detected following B19 infection [ 107 ] which are all transcribed solely from a single promoter P6 located upstream of NS1 gene, but are alternatively spliced and terminated at two alternative polyadenylation sites (Fig. 38.12c ) either in the middle or on the far rightside of the genome. By using the poly (A) site in the middle of virus genome, the P6 transcript has an intron in the NS1 ORF and splicing of this intron from NS1 transcript may create a novel ORF to encode a small accessory 7.5-kDa protein. However, if the poly (A) site on the right-side genome is used for RNA polyadenylation, the P6 transcript become a bicistronic (NS1 and VP) transcript with two introns. By splicing to remove the intron 1 from the bicistronic RNA, the single-spliced P6 transcript is capable to encode both 7.5-kDa and VP1 proteins. Double RNA splicing to remove both intron 1 and intron 2 from the P6 bicistronic transcript disrupts both ORFs for NS1 and VP1, but creates a VP2 or a novel ORF for another accessory 11-kDa protein, depending on which alternative 3 ¢ splice site being selected (Fig. 38.12c ) . Thus, all detected B19 transcripts are derived from a P6 pre-mRNA containing one or two introns with two alternative 3 ¢ splice site, depending on the selection of which one of two alternative poly A sites, and are alternatively spliced RNA transcripts, except the unspliced full-length NS1RNA. The cis -elements in the central exon and intron 2 are regulatory elements to control the alternative P6 RNA splicing, with the double spliced P6 RNAs being the predominant species in the infected cells [ 107 ] .

The most common infection by adenoviruses in humans occurs in upper respiratory tract causing bronchitis and pneumonia. Adenovirus infection can also induce a wide range of other symptoms including conjunctivitis, ear infection, gastroenteritis, myocarditis, hemorrhagic cystitis, meningitis, and encephalitis. There are 56 adenovirus types belonging to seven species (human adenovirus A-G). Types belonging to B and C are responsible for most respiratory infections, B and D for conjunctivitis, and F and G for gastroenteritis [ 108 ] . Adenoviruses were also found in other vertebrates.

Even though the human adenoviruses are not etiologically linked to any human cancer, some adenoviruses (types 2, 5, 12, 18, and 31) can, under special circumstances, transform rodent cells in vitro and induces tumors in small animals. Transformation activities are linked to two oncogenes E1A, which bind tumor suppressor pRB, and E1B, which binds tumor suppressor p53 [ 109 ] .

Adenoviruses are nonenveloped viruses with icosahedral architecture and contain a linear, nonsegmented, double-stranded DNA genome in size of ~26-45-kb which is capable to encode 22-40 different gene products [ 109 ] . Adenoviruses replicates in the nucleus of infected cells (Fig. 38.13a ) . The early stage of virus infection is characteristic with the expression of nonstructural early protein, while viral structural proteins are expressed in the late stage of viral DNA replication marking switch between two infection phases.

Almost all adenoviral early and late transcripts undergo RNA splicing in order to produce their corresponding viral products [ 110 ] . Viral E1A and L1 transcripts are exempli fi ed in this chapter for alternative RNA splicing seen in adenovirus infections.

Adenovirus E1A primary transcript contains three 5 ¢ splice donor sites and two 3 ¢ acceptor sites and is composed of three exons and two introns. The fi rst intron between by D1 and A1 is a suboptimal, minor intron. The second intron is a major intron which uses two alternative donor sites D2 and D3 and one acceptor site A2 for RNA splicing. Alternative splicing of E1A RNA through usage of various combinations of splice donor and acceptor sites leads to formation of fi ve species (13S, 12S, 11S, 10S, and 9S) of E1A mRNAs according to their sedimentation coef fi cient ( Fig. 38.13b ) and expression of individual unique protein [ 111 ] .

Transcription of late genes starts predominantly from a major late promoter. The primary late transcript is then polyadenylated at one of fi ve polyadenylation sites, forming fi ve groups of late transcripts (L1-L5). Each late mRNA contains a 201-nt "leader" sequence derived from three noncoding exons which function as a translational enhancer [ 112 ] . There are two variants of leader sequence with or without i -leader exon. Beside the leader sequence region, L1 transcripts are also alternatively spliced by using a common 5 ¢ splice site in combination with two alternative 3 ¢ splice sites. Selection of a proximal 3 ¢ splice site results in formation of 52, 55K RNA and selection of a distal 3 ¢ splice site produces IIIa mRNA (Fig. 38.13c ) .

Characteristic feature of adenovirus splicing is depending on the stage of virus infection. For example, E1A 13S and 12S mRNA are two major spliced products during early virus infection. In contrary, 9S RNA is highly accumulated in the late stage of infection [ 113 ] . Similar phenomenon was observed in the expression of late mRNAs. Inclusion of the i -leader exon is generally a signature of early transcripts, but most of the late transcripts contain the classical tripartite leader. While 52,55K L1 RNA is produced during both early and late infection, the IIIa splice site is used and IIIa transcripts and exon junction probes for speci fi c detection of spliced L1 isoforms from adenovirus type 2 by in situ hybridization as described [ 212 ] only in the late stage of viral infection [ 114 ] . Both cellular splicing machinery and viral products have been found to regulate alternative splicing of adenoviral transcripts in the course of viral infection (see reviews refs. [ 110, 115 ] ).

Polyomaviruses are small nonenveloped viruses which contains a circular doublestranded DNA (dsDNA) genome in size of ~5,000-bps. Polyomaviruses infect wide range of mammalian and avian species, but each virus exhibits a limited host range and narrow tissue tropism. The Polyomaviridae family contains only one genus Polyomavirus ( PyV ) which has nine members of human polyomaviruses: BKPyV [ 116 ] , JCPyV [ 117 ] , KI PyV [ 118 ] , WU PyV [ 119 ] , Merkel cell PyV (MCPyV) [ 120 ] , HPyV6, HPyV7 [ 121 ] , trichodysplasia spinulosa-associated PyV (TSV) [ 122 ] , and most recently discovered HPyV9 [ 123 ] . Simian vacuolating virus 40 (SV40), a prototype virus of the family, was introduced into human population as a contaminant in early trials of poliovirus vaccine [ 124 ] . Serological data indicate that polyomavirus infection is widespread in general human population with initial infection occurring in childhood [ 125 ] . After infection polyomaviruses persist in host for the rest of the life. While initial infection is mostly asymptomatic, several human polyomaviruses are associated with various pathological conditions in immunocompromised patients including nephropathy and cystitis associated with BK PyV and progressive multifocal leukoencephalopathy associated with JC PyV [ 126 ] , or trichodysplasia spinulosa presumably associated with TSV infection. Polyomaviruses express an oncoprotein T antigen and may lead to development of human cancer by abortive infection as has recently been con fi rmed in a rare but aggressive Merkel cell carcinoma [127] [128] [129] .

Polyomavirus genome consists of three functional regions: two protein-coding regions (early and late) divided by a noncoding control region (NCCR) (Fig. 38.14a ). Early and late transcripts are expressed in an opposite direction from promoters located in the NCCR which also contains origin of replication. Early transcripts encode nonstructural viral regulatory proteins (T [tumor] antigens) important for virus replication and modulation of cell cycle. Viral DNA replication initiates transcription of viral late genes to encode several viral capsid proteins.

In polyomavirus-infected cells, multiple isoforms of T antigen are detectable as a result of alternative RNA splicing. The primary transcript of T antigen contains two introns, but its intron 1 has two alternative 5 ¢ splice sites. During RNA splicing, the intron 2 retention is important for production of both large T and small t antigens. However, selection of a proximal 5 ¢ splice site in the intron 1 for RNA splicing leads to production of large T antigen, whereas selection of a distal 5 ¢ splice site in the intron 1 results in small t production. Because the sequence region between the proximal 5 ¢ splice site and the distal 5 ¢ splice site has a stop codon, retention of this region in small t RNA splicing makes the small t RNA larger than the large T RNA, but introduction of a premature stop codon in the small t RNA results in production of a smaller protein (Fig. 38.14b ) . In addition, a rare tiny-t antigen in size of ~17-kDa has been attributed to double RNA splicing in SV40-infected cells [ 130 ] . In this case, the transcript encoding the 17-kDa antigen shows splicing of both introns, but splicing of the intron 1 by selection of the proximal 5 ¢ ss. Similar to SV40, the multiple-spliced RNA species of early transcripts were detected also in other polyomaviruses such as truncated T-antigen (truncTAg) in BKPyV [ 131 ] , T ¢ 135, T ¢ 136 and T ¢ 165 in JCPyV [ 132 ] and T3 and T4 early transcripts in MCPyV [ 127 ] (Fig. 38.14b ) . 

Human papillomaviruses (HPVs) are a group of small DNA tumor viruses and has a genome in size of ~8-kb surrounded by a viral capsid. HPV genome consists of three regions: viral early, late, and noncoding regions and in general encodes eight viral genes (E1, E2, E4, E5, E6, E7, L1, and L2). Viral early gene products are regulatory proteins responsible for virus multiplication and pathogenesis during a productive infection, whereas L1 and L2 genes encode two viral capsid proteins for virus particle formation. Interestingly, almost all viral early genes are expressed from an early promoter upstream of viral E6 gene and are polyadenylated at an early poly (A) signal downstream of E5 gene. Thus, viral early gene transcripts are polycistronic, with several ORFs in a single RNA molecule, and undergo extensive alternative RNA splicing during viral RNA maturation. In contrast, viral L1 and L2 are commonly transcribed from E7 ORF and polyadenylated at a late poly (A) site downstream of L1 ORF (Fig. 38.15a ) . As a result, the 5 ¢ sequences of viral L1 and L2 are part of the viral early transcript sequences. RNA splicing to removal the most of these early gene sequences from the RNA by RNA splicing is important for viral L1 and L2 expression [ 133 ] . HPVs are the etiological agent of cervical cancer and presumably of other anogenital cancers. HPV is present in >95 % of all cervical cancer and is required for initiation of cervical carcinogenesis and maintenance of the cervical cancer cells. Cervical cancer is a leading cause for women death in the developing world, with about 493,000 new cases and nearly 273,000 deaths each year ( www.who.int/hpvcentre ). More than 120 genotypes of HPVs have been identi fi ed to date and are grouped into two major groups according to their pathogenesis and association with cervical cancer [ 134 ] . The high-risk or oncogenic HPV types are present in cervical cancers, whereas low-risk or nononcogenic HPVs are not found in cervical or other anogenital cancers [ 135 ] . In general, women acquire HPV infection by sexual contact. Various epidemiology studies indicate that women with repeat exposure to oncogenic HPVs and with persistent cervical infection of oncogenic HPVs are in high risk to develop cervical cancer [ 136, 137 ] . Infection with oncogenic HPV-16 and HPV-18, two most common oncogenic HPV types, leads to development of almost 70 % of all cervical and other anogenital cancers. Viral E6 and E7 of oncogenic HPVs are two viral oncoproteins that inactivate, respectively, cellular p53 and pRB, two tumor suppressor proteins essential for cell cycle control [ 138, 139 ] . In cervical cancer tissues and cervical cancer-derived cell lines, E6 and E7 oncogenes are highly expressed and majority of the E6/E7 bicistronic RNA are alternatively spliced as diagramed for HPV-16 and HPV-18 (Fig. 38.15b ) . A major spliced RNA isoform of viral E6/E7 bicistronic RNA is E6*I derived from splicing of nt 226 5 ¢ splice site to nt 409 3 ¢ splice site for HPV-16 and of nt 233 5 ¢ splice site to nt 416 3 ¢ splice site for HPV-18 ( Fig. 38.15b ). It has been demonstrated that this RNA splicing is necessary for viral E7 translation [ 140 ] and can be easily detected by RNase protection assay (RPA) or RT-PCR methods [ 140, 141 ] . The presence of high-grade premalignant lesions (CIN, cervical intraepithelial neoplasia) caused by oncogenic HPV infection is a sign of increased risk of developing cervical cancer. These lesions can be detected by routine cervical examination and treated by surgery to prevent progression to cervical cancer. Papanicolaou test (also called Pap smear) is a screening test used in gynecology to detect premalignant and malignant cells in cervical swabs. A woman who has Pap smear with abnormal cells may also be referred for HPV DNA testing by two FDA-approved assays: Hybrid Capture 2 DNA test to detect 13 high-risk HPVs (HPV- 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) from Qiagen [ 142 ] or Cobas 4800 System to detect 14 high-risk HPVs (HPV- 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) from Roche [ 143 ] . More recently, a few of HPV E6/E7 RNA tests have been introduced. APTIMA HPV Assay from Gen-Probe was designed to detect HPV E6/ E7 mRNA from 14 high-risk types (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68) [ 144 ] with a sensitivity and speci fi city similar to or better than Hybrid Capture 2 DNA test [ 145, 146 ] . PreTect HPV-Proofer from NorChip was designed to detect E6 and E7 RNA from HPV types 16, 18, 31, 33, and 45 [ 147, 148 ] , with more speci fi c than HC2 in identifying women with CIN 2+ but has a lower sensitivity [ 149 ] . By using the primers detailed in Fig. 38 .15c for RT-PCR assays, the spliced E6/E7 RNAs of HPV-16 and HPV-18 can be detected easily based on the amplicon size smaller than E6/E7 DNA, without worry of carryover viral DNA contamination encountered by HPV DNA tests.

Herpesviruses are large DNA viruses with complex life cycle. Their relatively large linear double-stranded DNA (dsDNA) genome (~100-200-kb) is encapsulated in a capsid with icosahedral architecture. Capsid is covered with heterogeneous layer of viral proteins and RNAs called tegument. Outside of the tegument is a lipid bilayer membrane (envelope) containing several virus-encoded glycoproteins. A hallmark of herpesvirus infection is to establish life-long "latent" infection in their host following initial infection. Latent virus is often reactivated by various stimuli causing recurrent infections-a typical feature of all herpesviruses.

Currently there are more than 100 known herpesviruses infecting wide range of animal species. All human herpesviruses belong to Herpesviridae family which is further grouped into four subfamilies: Alphaherpesvirinae , Betaherpesvirinae , Gammaherpesvirinae , and unassigned viruses. As of today, eight herpesvirus species have been isolated from humans and they are assigned to three subfamilies of Herpesviridae . These include the following: herpes simplex virus type 1 [HSV-1, also referred as human herpesvirus 1 (HHV1)], herpes simplex virus type 2 (HSV-2 or HHV2), Varicella-zoster virus (VZV or HHV3), Epstein-Barr virus (EBV or HHV4), human cytomegalovirus (CMV or HCMV or HHV5), human herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), and Kaposi sarcoma-associated herpesvirus (KSHV or HHV8).

Herpesviruses replicate in the nucleus. After virus entry the viral genome is translocated to the nucleus of infected cells where expression of viral genes occurs. All herpesviruses have two types of viral life cycle, latent and lytic, with distinctive transcriptional pro fi le. Latent infection is characterized with the expression of a few viral genes (latent transcripts) to maintain viral genome in latently infected cells. Lytic infection is associated with viral genome replication and production of infectious virions and generally leads to destruction of infected cell. In contrast to latent infection almost all of viral lytic genes in viral lytic infection are expressed in timely regulated fashion and are divided, based on their dependence on viral protein expression and viral genome replication, into three kinetic classes: immediate early, early, and late. At some circumstances the virus in latently infected cells may be reactivated and proceeded to lytic infection. The mechanisms controlling the establishment of latency and reactivation of herpesviruses are not fully understood. Herpesviral genome encodes up to 100 different genes including a variable number of noncoding genes for noncoding RNAs or viral miRNAs [150] [151] [152] .

Most human herpesviruses are highly prevalent in general population. Initial infection generally occurs in childhood or early adolescence through body contact and follows by establishment of latent infection. Some herpesviruses are sexually transmitted. Blood transfusion, tissue transplantation or congenital transmission represents other ways of acquiring the virus. Primary infection often occurs at epithelia, the point of entry, followed by establishment of latent infection generally in a specialized cell type (neurons or lymphocytes) which serves as a virus reservoir. Recurrence of infection is caused by virus reactivation from latency when virus escapes from host immunological surveillance. Overall symptoms of herpesvirus infections in healthy individuals are generally mild, but may be life threatening in immunocompromised patients. While infections of some herpesviruses such as EBV and KSHV are clearly etiologically linked to the development of several types of cancer, the role of other human herpesviruses in cell transformation remains unknown [ 153 ] . Several compounds are used to treat acute herpesvirus infection. No vaccine against herpesviruses is currently available.

The infections by herpesviruses are most commonly diagnosed by the presence of speci fi c antibodies and antigens or by detection of viral DNA by PCR. However, without quanti fi cation in multiple time points these techniques cannot distinguish virus carriers from patients with active virus replication. Detection of viral transcripts associated with virus lytic phase by RT-PCR provides indication of active virus replication, but often leads to a false-positive result due to viral DNA contamination. DNA contamination problem could be avoided by selection of an amplicon over the intron in spliced viral transcripts, a speci fi c product of the spliced RNA could be distinguished from its corresponding to DNA based on its size. The number of spliced viral transcripts varies from one herpesvirus to another, with only handful split genes in HSV-1 to about 30 % in KSHV [ 154 ] . Both latent and lytic genes could have an intron and sometimes are alternatively spliced.

HSV-1, a member of Alphaherpesvirinae subfamily, is an human neurotropic herpesvirus associated with "herpes labialis," Bell's palsy and vestibular neuritis [ 155 ] . After initial infection, HSV-1 establishes the latent infection in sensory neural ganglia from where it periodically reactivates. Viral genome consists of two unique regions (long and short) fl anked with inverted repeat regions (internal or terminal) (Fig. 38.16a ) . HSV-1 encodes at least 84 genes. The majority of gene are named based on their position within a particular part of viral genome like UL1 (unique long region ORF1) or US3 (unique short region ORF3) while others have alternative historical manes, like ICP0 (infected cells protein 0). Only few HSV-1 transcripts are spliced (LAT, ICP0, UL15, US1, US12/ICP47) (see review ref. [ 156 ] ) including both latent and lytic transcripts.

During latency HSV-1 expressed LAT ( l atency-a ssociated t ranscript) RNA from a repeat region of viral genome called LAT-DNA [ 157, 158 ] . Two forms of LAT RNAs are detectable in latently infected neurons. A major 2.0-kb RNA is produced by splicing of a capped and polyadenylated 8.3-kb primary transcript and represents a unique stable intron while spliced exonic RNA is unstable and quickly degraded [ 159 ] . A minor 1.5-kb RNA is generated by further splicing of the 2.0-kb RNA by removing an intron of 559 or 556-bp depending on the virus strain [ 160 ] (Fig. 38.16a ). Both LAT RNAs are uncapped without a poly A tail and accumulates in the nucleus of infected cells. HSV-1 LAT RNA is a noncoding regulatory RNA for establishment and maintenance of viral latency by inhibiting expression of viral lytic genes and interfering with cellular apoptosis pathway [ 161 ] . Recent studies showed that LAT transcript functions as a precursor for generation of virus-encoded miRNAs [ 162 ] . Expression from LAT-DNA was observed also during lytic infection. Lytic LAT transcripts differ from latent LAT RNA by the presence of a poly A tail [ 163 ] .

ICP0 (IE110) is encoded by a gene located in a viral genome repeat region and partially overlaps with LAT transcripts. Antisense expression of LAT transcripts inhibits the expression of ICP0 during latency. ICP0 is an immediate early gene expressed in the early stage of lytic infection. ICP0 functions as a nonspeci fi c transactivator and a cofactor of another viral transactivator ICP4 [ 164 ] . ICP0 initiates lytic replication in both newly infected cells as well as after reactivation in cells with latent infection. ICP0 is transcribed in reverse orientation from viral genome and its pre-mRNA contains three exons separated by two introns [ 165 ] (Fig. 38.16a ). After splicing, the mature mRNA encodes ICP0 protein with 775 aa residues. An alternatively spliced ICP0 transcript retaining intron 2 is detectable in the infected cells [ 166 ] and encodes a truncated ICP0R in size of 262-aa residues due to the presence of a stop codon in the intron 2. Thus, both ICP0 and ICP0R have the same aa sequences in the N-terminal part. ICP0R functions as a repressor of viral expression [ 167 ] .

HSV-2 represents another important human pathogen belonging to the alpha herpesvirus subfamily. Genital infection with HSV-2 causes genital herpes which is considered as a sexually transmitted disease. HSV-2 is also neurotropic and establishes latent infection in sacral ganglia. HSV-1 and HSV-2 are two closely related viruses with a similar genome and gene structures including their LAT and ICP0 regions [ 168 ] . In general the infection of HSV-1 and -2 is controlled by host immune system. Thus initial or recurrent infections are associated with only mild symptoms. Infection in immunocompromised patients could cause several severe diseases including encephalitis [ 169 ] . Genital infections or reactivation of HSV-2 during pregnancy could lead to congenital infection [ 170 ] . Detection of viral DNA may not provide suf fi cient information about virus replication status due to the permanent presence of viral DNA in the infected cells. Detection viral lytic products, such as spliced ICP0 RNA, may be a better predictor of virus reactivation even before occurrence of clinical symptoms for early diagnosis enabling of early treatment. Disappearance of the detectable lytic products could be a sign of treatment ef fi ciency since the viral transcripts disappear earlier than viral DNA.

Human cytomegalovirus (HCMV) together with HHV-6 and HHV-7 belongs to Betaherpesvirnae . High prevalence of CMV infection has been noticed in 50-80 % human population. In majority of healthy individuals, the primary CMV infection occurs asymptomatically, but in some cases could be associated with sore throat, prolong fever or syndrome similar to infectious mononucleosis. After initial infection the virus remains latent in T cells for the rest of the host life without apparent symptoms. In contrast, the CMV infection in immunocompromised individuals, such as newborns, transplant recipients, people with AIDS or cancer patients, could lead to severe disease and even death. The symptoms include hepatitis, retinitis, colitis, pneumonia, encephalitis and others.

CMV has a large genome of about 220 kb capable to encode around 200 genes (reviewed in ref. [ 171 ] ). While the majority of CMV transcripts are intronless, the presence of several split genes has been identi fi ed in all kinetic classes of viral genes [ 172 ] . A major immediate early region (MIE) located within a unique long (UL) region of CMV genome contains several genes highly expressed at the early stage of viral lytic infection. These include UL123 (IE1), UL122 (IE2), and UL119-115. MIE transcripts contain multiple introns and undergo complex alternative RNA Fig. 38.16 (continued) Shown below are two representatives of HSV-1 RNA splicing, latency associated transcript (LAT) and immediate-early ICP0 transcripts with positions of 5 ¢ and 3 ¢ splice sites, and primer pairs ( arrows below ) used for detection of spliced transcripts as detailed in the table further below. Boxes (full for LAT and empty for ICP0) represent exons divided by introns ( dashed lines ). The primer pairs in the table were described by Tanaka et al. [ 214 ] , with nucleotide positions in HSV-1 genome (GenBank Accs. No. X14112.1). ( b ) Genome structure of human cytomegalovirus (see other details in ( a )). Shown below the genome structure are spliced transcripts of late UL21.5 gene and two immediate early genes UL123 (IE1) and UL122 (IE2) expressed from a major immediate early region (MIE). Boxes or solid lines are exons and dashes are introns or splicing directions. P promoter, pA polyadenylation site. Arrows below UL21.5 transcripts are primer pairs used for detection of spliced UL21.5 transcripts by nested RT-PCR as described [ 174 ] and detailed in the table below, with the nucleotide positions in HCMV genome (strain AD169, GenBank Accs. No. X17403. 1) splicing. MIE transcripts IE1 and IE2 are expressed from the same promoter, but alternatively polyadenylated. These transcripts have fi ve major exons and can be alternatively spliced to express additional isoforms of IE1 and IE2 proteins (Fig. 38.16b ) . Splicing was detected also in transcripts from other CMV genes such as TRL4, UL89, US3, R160461, and R27080 [ 172 ] . Gene UL21.5 (previously named as R27080) is one of the known CMV split late genes (SLG). The UL21.5 transcript which encodes viral glycoprotein is expressed from the UL region posited from nt 27,080 to nt 27,574 of CMV genome [ 173 ] , and has a short intron with 83 nts. Removal of this intron leads to production of a mature mRNA in size of ~0.4-kb (Fig. 38.16b ) . Both spliced and unspliced UL21.5 RNAs are easily detectable by RT-PCR from infected cells [ 174 ] .

Allogenic bone marrow transplant recipients are in high risk to develop CMV diseases. Historically, viremia was used as an indicator of CMV disease to guide preemptive treatment. Multiple approaches have been developed to detect CMV viremia in circulating lymphocytes by direct virus isolation with cultivation or by detection of viral antigens or viral DNA [ 175, 176 ] . However, the detection of viremia is not suf fi cient in disease prediction since many viremic patients never develop symptoms. An active CMV replication in peripheral blood lymphocytes can be veri fi ed by analyzing viral mRNAs [ 177 ] . Ampli fi cation of spliced viral transcripts has some advantages in comparison to intronless transcripts, with no worry by DNA contamination. Detection of spliced immediate early transcripts had been reported in good correlation with detection of viral DNA or viral antigen [178] [179] [180] . Detection of late gene UL21.5 has better prediction value and signi fi cantly correlates with disease progression [ 174, 181, 182 ] .

Epstein-Barr virus (EBV), a well-characterized member of Gammaherpesvirinae subfamily, is an important human pathogen. EBV infection is highly prevalent, with more than 95 % of human population become seropositive in early life. While primary infection during childhood is unremarkable, the virus acquisition in adolescence and adulthood is often associated with the development of infectious mononucleosis. In healthy individuals the EBV infection is well controlled by immune system. However, EBV remains in long-living memory B cells where it establishes a latent infection. EBV is an oncogenic virus capable to transform the infected B cells [ 183 ] . EBV infections have been associated with the development of several human malignancies, including nasopharyngeal carcinoma, Burkitt's lymphoma, Hodgkin's lymphoma, gastric carcinoma, and others (see review ref. [ 184 ] ). Active EBV replication due to immunosuppression may cause posttransplant lymphoproliferative disease [ 185 ] . During latent infection, EBV expresses six nuclear antigens (EBNAs-1, -2, -3A, -3B, -3C, and -LP), three latent membrane proteins (LMPs-1, -2A, and -2B) and several noncoding transcripts (EBERs-1 and -2 and BARTs). Many EBV latent products are de fi ned as oncogenes responsible for EBV-mediated cell transformation [ 115 ] . Several types of EBV latency were de fi ned by variable expression of latent genes in various malignancies [ 186 ] .

EBV genome (~172-kb) is fl anked by multiple terminal repeats (TR) and can be divided into a long and a short unique region (U L and U S ) by internal repeat 1 (IR1) (Fig. 38.17a ) . EBV encodes at least 80 viral proteins [ 187 ] and several noncoding RNAs including viral miRNAs [ 188, 189 ] . The ORF names are derived from their positions in Bam HI fragment (from A to Z) by orientation (L-left or R-right) and a digital number representing the frame (F) order (for example BZLF1). Other genes retain their historical names based on the gene product function. Number of split genes in EBV is signi fi cantly higher than that found in alpha-and beta-herpesviruses. Extensive alternative RNA splicing is prominent especially for almost all EBV latent transcripts, but the transcripts of many lytic genes are also spliced.

EBNA-1 is a multifunctional viral protein critical for establishing and maintaining EBV latency and for regulation of viral promoter activities [ 190 ] . In infected cells, EBNA-1 is expressed from a spliced mRNA derived from a primary transcript in size of ~100 kb. This transcript is originated from one of two alternative promoters, Cp or Wp, which are named by their localization in a particular Bam HI fragment of viral genome (Fig. 38.17b ). At the early stage of latent infection, the Wp is initially used, but the expressed EBNA1 and EBNA2 from the Wp transactivate the Cp promoter and cause a switch of transcription from Wp to Cp [ 191 ] . Usage of Cp promoter is associated with EBV "latency type III." In Burkitt's lymphoma and Burkitt's lymphoma-derived cell lines, EBNA1 expression is initiated from a distal Qp promoter rather than from Cp and Wp and is associated with "latency type I" [ 192 ] . EBNA is expressed also in the lytic phase from additional Fp promoter closely localized upstream to the Qp promoter [ 193 ] .

The establishment of active EBV replication after virus reactivation from latency is dependent on the expression of two immediate-early genes BZLF1 and BRLF1 [ 194 ] to encode viral transactivators ZEBRA (BZLF1) and RTA (BRLF1). Although BRLF1 and BZLF1 are transcribed separately from a different promoter with the Rp for BRLF1 and the Zp for BZLF1, both gene transcripts utilize the same polyadenylation site for RNA polyadenylation [ 195 ] (Fig. 38.17c ) . Thus, the Zp promoter transcript is a monocistronic ZEBRA RNA containing two constitutive introns and splicing of these two introns results in production of a 0.9-kb mRNA to encode ZEBRA protein. Transcription from the Rp promoter leads to produce a 3.8-kb bicistronic transcript, ZEBRA/RTA, which contains two additional introns over the ZEBRA RNA. Splicing of the intron 1 in the 5 ¢ noncoding region of ZEBRA/RTA transcript leads to production of a 2.9-kb RNA as a major RNA isoform. However, both isoforms of ZEBRA/RTA RNA have a potential to encode ZEBRA and RTA proteins. A third, minor isoform of ZEBRA/RTA transcript is derived from splicing of additional internal intron spanning over BRLF1 ORF to BZLF1 ORF and this splicing produces a RAZ transcript in size of ~0.9-kb to encode a RTA-ZEBRA fusion protein, RAZ. RAZ may function as an inhibitor to ZEBRA during EBV infection [ 196 ] .

Transcripts for EBNA-1 are believed to be expressed in all forms of EBV latent infection except of latently infected nondividing B-cells with "latency type 0." This makes the detection of EBNA-1 expression as a good marker for the presence of EBV in tumors. The expression of ZEBRA during lytic infection could be used to monitor a productive EBV infection and EBV reactivation.

Kaposi sarcoma-associated herpesvirus (KSHV) is the latest discovered human herpesvirus [ 197 ] . After primary infection, KSHV establishes latent infection in endothelial cells and B cells [ 198 ] . In healthy individuals both primary and latent KSHV infections are generally asymptomatic. Suppression of immune system in KSHV-positive individuals, such as AIDS patients or tissue transplant recipients, is associated with the development of several cancers including all forms of Kaposi sarcoma (a solid tumor of endothelial origin) or B-cell lymphomas [primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD)] (see review ref. [ 199 ] ). Presence of viral genome and expression of viral-encoded products in all cancer cells support active roles of KSHV in cell transformation. KSHV belongs to Gammaherpesvirinae and has similar genome organization as EBV with long unique region fl anked with terminal repeats (Fig. 38.18a ) . KSHV genome (~165 kb) encodes up to 90 genes named by their position in viral genome from left to right (for example ORF47) [ 200 ] . Some genes are designated with digital K number, like K2, while some have alternative names based on their function (ORF57 or MTA-mRNA transcript accumulation). KSHV transcripts derived from ~30 % viral genes, including both latent and lytic genes, undergo RNA splicing [ 154 ] .

During latency, KSHV genome expresses a latency-associated nuclear antigen-1 (LANA-1) [ 201 ] from ORF73. The gene ORF73 posits along with ORF72 and K13 in a larger latent locus of the virus genome. The latter two genes encode viral homologues of cellular proteins vCyclin (ORF72) and vFLICE (K13). ORF73/72/K13 are transcribed from a single promoter (P 127880 ) as a tricistronic RNA which has an intron containing two alternative 3 ¢ splice site. Alternative RNA splicing and alternative A detailed EBNA-1 transcript derived from the Q p promoter is shown below with splice sites ( black triangles ) and splice directions ( dashed lines for introns). A primer pair used to detect the spliced EBNA1 transcript from exon U to exon K [ 185 ] are detailed in the table below. (c) Gene structures of BRLF1 (RTA) and BZLF1 (ZEBRA) (two EBV-immediate early genes) and their spliced RNA products. EBV RTA and ZEBRA are transcribed by two alternative promoters, R P and Z P , but polyadenylated by using the same polyadenylation signal downstream of ZEBRA ORF. Thus, the bicistronic RTA transcript derived from Rp promoter contains multiple introns and has potentials to encode RTA, ZEBRA, and RAZ proteins by alternative RNA splicing, whereas the monocistronic ZEBRA transcript derived from the Zp promoter encodes only ZEBRA protein and also contains multiple introns as detailed further below with nucleotide positions of splice sites, exons (Z1-Z3, black boxes ) and introns ( dashed lines ). Arrows below exons Z1 and Z3 are a primer pair used for detection of spliced ZEBRA mRNA [ 185 ] and detailed in the RNA polyadenylation of the tricistronic pre-mRNA results in production of three mature mRNAs (5.4-, 3.3-, and 1.7-kb) [ 202 ] (Fig. 38.18b ) . The 5.4-kb transcript most likely for LANA-1 expression is produced by usage of the proximal 3 ¢ splice site, whereas usage of the distal 3 ¢ splice site leads to express the 1.7-kb transcript for vCyclin and vFLICE. Both transcripts are polyadenylated at the same distal polyadenylation site. The minor 3.3-kb transcript use the proximal splice site for RNA splicing, but is polyadenylated at a proximal noncanonical polyadenylation signal (Fig. 38.18b ) . KSHV lytic replication is controlled by a major viral transactivator, ORF50 (also referred as Rta) [ 203, 204 ] . Similarly to LANA1, ORF50 posits along with K8 and K8.1 in a larger gene locus (ORF50/K8/K8.1 cluster) (Fig. 38.18c ) and is expressed as an immediately early transcript during lytic virus replication. K8 encoding a viral k-bZIP protein is an early gene and K8.1 encoding a glycoprotein is a late gene. Although each of the three genes bears its own promoter, all of their RNA transcripts use a single polyadenylation site located downstream of K8.1 gene and undergo alternative RNA splicing (see review ref. [ 154 ] ). Thus, the 3 ¢ portion of ORF50 transcript is homologous to K8 and K8.1 and has the same intron and exon structures as seen in K8 and K8.1 transcripts. The ORF50 transcript is tricistronic, K8 is bicistronic, and K8.1 is monocistronic in nature. The bicistronic K8 full transcript composes of four exons separated by three introns (Fig. 38.18c ) . A functional K8 a protein is expressed from a fully spliced mRNA, but retention of the intron 2 in K8 b mRNA results in the expression of a minor form K8 b protein [ 205 ] . An unspliced K8 RNA, K8 g , is also detectable, but rare in lytically infected cells.

In summary, LANA-1 expression is a hallmark of KSHV latent infection. Transcripts originated from the ORF73/72/K13 gene cluster are expressed in latently infected, KSHV-transformed cells and are detectable by RT-PCR. Active virus replication is associated with the expression of viral lytic genes. Ampli fi cation of spliced K8 region which detects the expression of both ORF50 tricistronic and K8 bicistronic transcripts could be used to monitor viral lytic replication [ 206 ] . [ 215 ] as detailed in the table below . (c) Gene structures of a KSHV lytic locus consisting of immediate early RTA (ORF50), early K8 and late K8.1 genes. Three genes are expressed from three separate promoters (P), but all of their transcripts ( full lines with arrows immediately below to the right) are polyadenylated at the same polyadenylation site (pA), resulting in RTA as a tricistronic, K8 as a bicistronic, and K8.1 as a monocistronic transcript. The enlarged K8 coding region contains three exons ( fi lled boxes ) and two introns ( dashed lines ), with nucleotide positions of each splice site in the KSHV genome (GenBank Accs. No. U75698.1). Names of three common forms of K8 transcripts from alternative RNA splicing are shown on the left. oST1 and oST3 are two primers used to detect spliced K8 RNAs as described [ 215, 216 ] and are detailed in the table below

The major aim of this chapter is to provide our readers with knowledge of viral RNA splicing during viral infection and the detection of spliced viral RNA transcripts as a new approach in diagnostic virology. In the fi rst part, we provided basic information about the mechanisms of RNA splicing and methodological approaches of speci fi c detection of spliced RNA molecules. The core of these techniques represents an ampli fi cation and detection of nucleic acids. The advantage of nucleic acid-based techniques is the application of the same platform for detection various viral pathogens often in the same time by multiplexing. The rapid setup of these methods is especially important for quick response to emerging viruses as has recently been proven in the case of SARS and avian fl u pandemic, when nucleic acid ampli fi cation was rapidly employed to detect and to con fi rm the infection. The less material requirement and simplicity make these detection methods suitable for applications in low resources setting such laboratories of the fi rst contact and fi eld laboratories. Because ampli fi cation of nucleic acid molecules as a routine in many diagnostic laboratories is used to detect the genomic sequences from many viruses, the detection of spliced viral transcripts could be performed simultaneously to already existing methods.

The second part of the chapter summarized our current knowledge about viral RNA splicing events in the majority of known human viruses. We also included some viral agents, such as human circoviruses and adeno-associated viruses, where a direct link between infection and pathological manifestation remains to be determined. In addition, we have provided examples of each virus where the detection of spliced viral RNA could bring additional bene fi t to current techniques to improve the disease prognosis or better monitoring of ef fi ciency of therapeutic intervention. We believe that systematic study of RNA splicing events during viral infection could lead to better viral diagnosis, better therapy management, and eventually leading to our better understanding of pathogenesis of human viral pathogens.

Nucleic acid ampli fi cation and detection methods

Spliced segments at the 5 ¢ terminus of adenovirus 2 late mRNA

An amazing sequence arrangement at the 5 ¢ ends of adenovirus 2 messenger RNA

Capping, splicing, and 3 ¢ processing are independently stimulated by RNA polymerase II: different functions for different segments of the CTD

An extensive network of coupling among gene expression machines

A novel spliceosome containing U11, U12, and U5 snRNPs excises a minor class (AT-AC) intron in vitro

AT-AC pre-mRNA splicing mechanisms and conservation of minor introns in voltage-gated ion channel genes

Splicing of mRNA precursors: the role of RNAs and proteins in catalysis

Structural basis for exon recognition by a group II intron

Searching for splicing motifs

The SR protein family of splicing factors: master regulators of gene expression

Functional diversity of the hnRNPs: past, present and perspectives

Coupling transcription and alternative splicing

Epigenetics in alternative pre-mRNA splicing

Regulation of alternative RNA splicing by exon de fi nition and exon sequences in viral and mammalian gene expression

Alternative isoform regulation in human tissue transcriptomes

ISIS, the intron information system, reveals the high frequency of alternative splicing in the human genome

Oligonucleotides with fl uorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization

Molecular beacons: probes that fl uoresce upon hybridization

Detection of PCR products using self-probing amplicons and fl uorescence

Microarray analysis of RNA processing and modi fi cation

Microarray analysis of alternative splicing

Laser-assisted microdissection for real-time PCR sample preparation

Complementary techniques: laser capture microdissection-increasing speci fi city of gene expression pro fi ling of cancer specimens

In situ detection of Epstein-Barr virus and phenotype determination of EBV-infected cells

In situ hybridization and detection using nonisotopic probes

Tyramide signal ampli fi cation for DNA and mRNA in situ hybridization

Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development

PNA-based probe for quantitative chemiluminescent in situ hybridisation imaging of cellular parvovirus B19 replication kinetics

Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation

A practical approach to FRET-based PNA fl uorescence in situ hybridization

Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fi xed paraf fi n-embedded tissue sections without protease treatment

Next-generation sequencing and its applications in molecular diagnostics

Direct metagenomic detection of viral pathogens in nasal and fecal specimens using an unbiased high-throughput sequencing approach

Test of intron predictions reveals novel splice sites, alternatively spliced mRNAs and new introns in meiotically regulated genes of yeast

Initial sequencing and analysis of the human genome

The biology of in fl uenza viruses

Diversity of coding strategies in in fl uenza viruses

Segment 8 of the in fl uenza virus genome is unique in coding for two polypeptides

Sequence of interrupted and uninterrupted mRNAs and cloned DNA coding for the two overlapping nonstructural proteins of in fl uenza virus

In fl uenza B virus genome: sequences and structural organization of RNA segment 8 and the mRNAs coding for the NS1 and NS2 proteins

The in fl uenza C virus NS gene: evidence for a spliced mRNA and a second NS gene product (NS2 protein)

Sequences of mRNAs derived from genome RNA segment 7 of in fl uenza virus: colinear and interrupted mRNAs code for overlapping proteins

A novel spliced transcript of in fl uenza A/ WSN/33 virus

Mutations at alternative 5 ¢ splice sites of M1 mRNA negatively affect in fl uenza A virus viability and growth rate

Evidence that the matrix protein of in fl uenza C virus is coded for by a spliced mRNA

In fl uenza C virus CM2 integral membrane glycoprotein is produced from a polypeptide precursor by cleavage of an internal signal sequence

In fl uenza C virus CM2 protein is produced from a 374-amino-acid protein (P42) by signal peptidase cleavage

Chapter 1. Regulation of HIV-1 alternative RNA splicing and its role in virus replication

Cloning and functional analysis of multiply spliced mRNA species of human immunode fi ciency virus type 1

Alternative splicing: regulation of HIV-1 multiplication as a target for therapeutic action

Detection, characterization and regulation of antisense transcripts in HIV-1

Rev-mediated nuclear export of RNA is dominant over nuclear retention and is coupled to the Ran-GTPase cycle

A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability

A novel human immunode fi ciency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins

A tripartite HIV-1 tat-env-rev fusion protein

Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease

Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis

HTLV-I associated myelopathy, a new clinical entity

Geographic and molecular epidemiology of primate T lymphotropic retroviruses

Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression

HTLV-I antisense transcripts initiating in the 3 ¢ LTR are alternatively spliced and polyadenylated

Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription

A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology

TT virus as a human pathogen: signi fi cance and problems

Identi fi cation of a novel GC-rich 113-nucleotide region to complete the circular, single-stranded DNA genome of TT virus, the fi rst human circovirus

Molecular and biophysical characterization of TT virus: evidence for a new virus family infecting humans

TT virus mRNAs detected in the bone marrow cells from an infected individual

Three spliced mRNAs of TT virus transcribed from a plasmid containing the entire genome in COS1 cells

Human circovirus TT virus genotype 6 expresses six proteins following transfection of a full-length clone

Identi fi cation of a new human DNA virus (TTV-like mini virus, TLMV) intermediately related to TT virus and chicken anemia virus

Hepatocellular carcinoma: a global view

Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression

Hepatitis B virus biology

The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis

Hepatitis B virus transcript produced by RNA splicing

Detection and mapping of spliced RNA from a human hepatoma cell line transfected with the hepatitis B virus genome

Identi fi cation of a doubly spliced viral transcript joining the separated domains for putative protease and reverse transcriptase of hepatitis B virus

Alternative splicing of hepatitis B virus RNAs in HepG2 cells transfected with the viral DNA

Posttranscriptional control of HBV gene expression

Characterization of the contribution of spliced RNAs of hepatitis B virus to DNA synthesis in transfected cultures of Huh7 and HepG2 cells

In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA

Replication ef fi ciency and sequence analysis of full-length hepatitis B virus isolates from hepatocellular carcinoma tissues

Hepatitis B pregenomic RNA splicing-the products, the regulatory mechanisms and its biological signi fi cance

Identi fi cation and characterization of a structural protein of hepatitis B virus: a polymerase and surface fusion protein encoded by a spliced RNA

In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA

Role of the hepatitis B virus proteins in pro-and anti-apoptotic processes

Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2

Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells

Helper functions required for wild type and recombinant adeno-associated virus growth

The expanding range of parvoviruses which infect humans

Clades of adeno-associated viruses are widely disseminated in human tissues

DNA of adeno-associated virus (AAV) in testicular tissue and in abnormal semen samples

Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion

Parvovirus vectors: use and optimisation in cancer gene therapy

The adeno-associated virus type 2 Rep protein regulates RNA processing via interaction with the transcription template

A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication

Characterization of the transcription pro fi le of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses

Parvovirus-like particles in human sera

Identi fi cation and characterization of persistent human erythrovirus infection in blood donor samples

An outbreak of erythema infectiosum associated with human parvovirus infection

Clinical manifestations of human parvovirus B19 in adults

Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19)

Identi fi cation of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis

Novel transcription map for the B19 (human) pathogenic parvovirus

Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus

Temporal regulation of adenovirus major late alternative RNA splicing

Differential splicing yields novel adenovirus 5 E1A mRNAs that encode 30 kd and 35 kd proteins

Adenovirus-speci fi c translation by displacement of kinase Mnk1 from cap-initiation complex eIF4F

Remodelling of the host cell RNA splicing machinery during an adenovirus infection

Controls of RNA splicing and termination in the major late adenovirus transcription unit

Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses

New human papovavirus (B.K.) isolated from urine after renal transplantation

Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy

Identi fi cation of a third human polyomavirus

Identi fi cation of a novel polyomavirus from patients with acute respiratory tract infections

Clonal integration of a polyomavirus in human Merkel cell carcinoma

Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin

Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient

A novel human polyomavirus closely related to the African green monkey-derived lymphotropic polyomavirus

The vacuolating virus, S.V. 40

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40

Phylogenetics, evolution, and medical importance of polyomaviruses

T antigen mutations are a human tumor-speci fi c signature for Merkel cell polyomavirus

Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator

An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells

Independent expression of the transforming amino-terminal domain of SV40 large I antigen from an alternatively spliced third SV40 early mRNA

A truncated T antigen expressed from an alternatively spliced BK virus early mRNA

Identi fi cation of three new JC virus proteins generated by alternative splicing of the early viral mRNA

Papillomavirus genome structure, expression, and posttranscriptional regulation

Classi fi cation of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments

Epidemiologic classi fi cation of human papillomavirus types associated with cervical cancer

Human papillomavirus and cervical cancer

Persistence of type-speci fi c human papillomavirus infection and increased long-term risk of cervical cancer

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product

The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16-or type 18-positive cervical cancer cell lines via translation reinitiation

Construction of a full transcription map of human papillomavirus type 18 during productive viral infection

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-speci fi c HPV testing in clinical practice

High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study

Ef fi ciency of the APTIMA HPV Assay for detection of HPV RNA and DNA targets

Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more speci fi c at detecting cervical precancer and cancer

Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology

PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses

Sensitivity, speci fi city, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test

Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identi fi cation of women at risk of cervical cancer

Noncoding RNPs of viral origin

Herpesvirus microRNAs: phenotypes and functions

Viral miRNAs

Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV

Split genes and their expression in Kaposi's sarcoma-associated herpesvirus

Herpes Simplex Virus Type 1 infection: overview on relevant clinico-pathological features

Peculiarities of herpes simplex virus (HSV) transcription: an overview

A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state

Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene "anti-sense" transcript by in situ hybridization

Herpes simplex virus latency-associated transcript is a stable intron

Identi fi cation of a novel latency-speci fi c splice donor signal within the herpes simplex virus type 1 2.0-kilobase latency-associated transcript (LAT): translation inhibition of LAT open reading frames by the intron within the 2.0-kilobase LAT

Regulation of caspase 8-and caspase 9-induced apoptosis by the herpes simplex virus type 1 latency-associated transcript

MicroRNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs

Relationship between polyadenylated and nonpolyadenylated herpes simplex virus type 1 latency-associated transcripts

Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression

Characterization of the IE110 gene of herpes simplex virus type 1

A truncated form of herpes simplex virus type 1 immediate-early protein Vmw110 is expressed in a cell type dependent manner

Mutational analysis of ICP0R, a transrepressor protein created by alternative splicing of the ICP0 gene of herpes simplex virus type 1

An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor

Neurological complications of herpes simplex virus type 2 infection

Herpes simplex virus infection in pregnancy: diagnosis and signi fi cance

The DNA sequence of the human cytomegalovirus genome

Spliced transcripts of human cytomegalovirus

A subset of viral transcripts packaged within human cytomegalovirus particles

A polymerase chain reaction to detect a spliced late transcript of human cytomegalovirus in the blood of bone marrow transplant recipients

Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp 65) for optimal quantitation of human cytomegalovirus antigenemia

Association of cytomegalovirus infection with post-transplantation cardiac rejection as studied using the polymerase chain reaction

Quantitative competitive NASBA for measuring mRNA expression levels of the immediate early 1, late pp 67, and immune evasion genes US3, US6 and US11 in cells infected with human cytomegalovirus

Circulating immediate-early mRNA in patients with cytomegalovirus infections after solid organ transplantation

Detection of cytomegalovirus mRNA and DNA encoding the immediate early gene in peripheral blood leukocytes from immunocompromised patients

Identi fi cation of active cytomegalovirus infection by analysis of immediate-early, early and late transcripts in peripheral blood cells of immunode fi cient patients

Early detection of cytomegalovirus (CMV) infection in bone marrow transplant patients by reverse transcription-PCR for CMV spliced late gene UL21.5: a two site evaluation

Use of reverse transcription polymerase chain reaction with colorimetric plate hybridization to detect a cytomegalovirus late spliced mRNA in polymorphonuclear leukocytes from renal transplant patients

Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers

Spectrum of Epstein-Barr virus-associated diseases

Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads

EBV gene expression and regulation

DNA sequence and expression of the B95-8 Epstein-Barr virus genome

Noncoding RNAs produced by oncogenic human herpesviruses

EBV-encoded miRNAs

EBNA-1, a bifunctional transcriptional activator

Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes

The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element

Characterization of the Epstein-Barr virus Fp promoter

Lytic cycle switches of oncogenic human gammaherpesviruses

Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators

RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism

Identi fi cation of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma

KSHV infection and the pathogenesis of Kaposi's sarcoma

Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases

Nucleotide sequence of the Kaposi sarcomaassociated herpesvirus (HHV8)

Structure and function of latency-associated nuclear antigen

A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus

A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus

Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells

Kaposi's sarcoma-associated herpesvirus K8beta is derived from a spliced intermediate of K8 pre-mRNA and antagonizes K8alpha (K-bZIP) to induce p21 and p53 and blocks K8alpha-CDK2 interaction

Targeted disruption of Kaposi's sarcoma-associated herpesvirus ORF57 in the viral genome is detrimental for the expression of ORF59, K8alpha, and K8.1 and the production of infectious virus

Generation of recombinant in fl uenza A virus without M2 ion-channel protein by introduction of a point mutation at the 5 ¢ end of the viral intron

Alternative splicing of human immunode fi ciency virus type 1 mRNA modulates viral protein expression, replication, and infectivity

Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-speci fi c CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP)

Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance

Identi fi cation and characterization of a second novel human erythrovirus variant, A6

Regulation of adenovirus alternative RNA splicing correlates with a reorganization of splicing factors in the nucleus

Regulation of gene expression in primate polyomaviruses

Analysis by RNA-PCR of latency and reactivation of herpes simplex virus in multiple neuronal tissues

Kaposi's sarcoma-associated herpesvirus ORF57 functions as a viral splicing factor and promotes expression of intron-containing viral lytic genes in spliceosome-mediated RNA splicing

Kaposi's sarcoma-associated herpesvirus K8 exon 3 contains three 5 ¢ -splice sites and harbors a K8.1 transcription start site